AZD 1208
Alternative Names: AZD-1208Latest Information Update: 28 Jan 2024
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Small molecules
- Mechanism of Action PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Diffuse large B cell lymphoma; Prostate cancer
- Discontinued Acute myeloid leukaemia; Lymphoma; Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA (PO)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 05 Jun 2022 Pharmacodynamics data from a preclinical trial in acute myeloid leukaemia presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)